Sabbatical in Clinical Research Management Program
|
Training Initiative
|
FDA, OS
|
CC, FIC, NCATS, NEI, NHLBI, NIAID, NIDCR, NIDDK
|
2009
|
|
SARS-CoV-2 Assay Development, Training, and Standardization
|
Resource Development
|
FDA
|
NIAID
|
2020
|
|
SARS-CoV-2 Assessment of Viral Evolution Program (SAVE)
|
Committee, Advisory Group, or Work Group
|
FDA, CDC, ASPR
|
NIAID
|
2021
|
|
SARS-CoV-2 Interagency Group on Resistance to Medical Countermeasures (MCMs)
|
Committee, Advisory Group, or Work Group
|
ASPR, CDC, FDA
|
|
2021
|
|
SARS-CoV-2 Pathogenesis
|
Research Initiative
|
FDA
|
NIAID
|
2020
|
|
SARS-CoV-2 Virology Core
|
Research Initiative
|
FDA
|
NIAID
|
2020
|
|
SARS-CoV-2Interagency Working Group: Therapeutics, Diagnostics, Vaccines. DCR involved in Thx and DX (SIG)
|
Committee, Advisory Group, or Work Group
|
NIH, FDA, ASPR
|
NIAID
|
2021
|
|
Sequencing Quality Control Phase 2 (SEQC2)
|
Resource Development
|
FDA
|
NLM, CIT, NCI, NHLBI, NIEHS
|
2017
|
|
SHIELD Standardization of Lab Data to Enhance Outcomes Research and Value Based Care (SHIELD)
|
Committee, Advisory Group, or Work Group
|
FDA, CDC
|
|
2019
|
|
Sickle Cell Disease Federal Interagency Work Group (SCD FIWG)
|
Committee, Advisory Group, or Work Group
|
FDA, CDC, HRSA, OASH
|
NHLBI
|
2019
|
|
Smokefree.gov Initiative
|
Resource Development
|
CDC, FDA, IHS
|
NIMHD
|
2003
|
|
Somatic Cell Genome Editing
|
Research Initiative
|
FDA
|
NCATS, NCI, NHGRI, NHLBI, NIAID, NIAMS, NIDDK, NIMH, NINDS, OD/ DPCPSI/ ORIP, NIBIB, NEI, NICHD, NIDA, NIEHS
|
2017
|
|
Steering Committee of the Scientific Interest Group in Glycobiology
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, NHGRI, NHLBI, NIAID, NICHD, NIDCR, NIDDK, NIGMS
|
2008
|
|
STS/ACC TVT Registry
|
Meeting/ Workshop
|
CMS, FDA
|
|
|
|
Studies of the Natural History of Sickle Cell Disease
|
Research Initiative
|
FDA
|
NHLBI
|
|
|
Subcommittee on Open Science (Formerly Interagency Working Group on Open Science)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, ASPR, CDC, CMS, FDA
|
NLM, OD/ OER, OD/ OSP
|
2013
|
|
SUDV Medical Countermeasures Acceleration Meeting
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, HIS, SAMHSA
|
NIAID
|
|
|
Support for Implementation of Agency Public Access Policies
|
Resource Development
|
AHRQ, CDC, FDA, IOS, ASPR
|
OD/ OSP
|
2013
|
|
Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT)
|
Resource Development
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, SAMHSA
|
|
2003
|
|
Systems Immunology of COVID-19
|
Research Initiative
|
FDA
|
NIAID
|
2020
|
|
Systems immunology of influenza vaccination responses in healthy COVID-19 recovered individual versus those with no history of COVID-19
|
Research Initiative
|
FDA
|
NIAID
|
2021
|
|
|